A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril

Journal of Clinical Pharmacology

Volumn 36, Issue 5, 1996, Pages 414-421

  Breslin, Elaine ^a   Posvar, Edward ^a   Neub, Martin ^b   Trenk, Dietmar ^c   Jahnchen, E ^c  

^a PFIZER INC   (United States)

^b Heart Center Bad Krozingen ^*

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL; QUINAPRILAT;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0029991632     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb05028.x     Document Type: Article

References (12)

1. Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ: Overview of quinapril, a new ACE inhibitor. J Cardiovasc Pharmacol 1990;15(suppl 2):S14-S23.
2. Olson SC, Horvath AM, Michniewicz BM, Sedman AJ, Colburn WA, Welling PG: The clinical pharmacokinetics of quinapril. Angiology 1989;40:351-359.
3. Kaplan HR, Taylor DG, Olson SC, Andrews LK: Quinapril: a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology 1989;40:335-350.
4. Posvar EL, Legler UF, Sedman AJ, Jahnchen E: Effect of intravenous quinaprilat on angiotensin I pressor response (abstract). Clin Pharmacol Ther 1992;51:139.
5. Neub M, Legler U: Pharmacokinetics of intravenous quinaprilat following rising single and multiple doses (abstract). Naunyn Schmiedebergs Arch Pharmacol 1991;343(suppl):R128.
6. Belz GG, Essig J, Wellstein A: Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol 1987;9:219-224.
7. Wellstein A, Essig J, Belz GG: Inhibition of angiotensin-1 response by cilazapril and its time course in normal volunteers. Clin Pharmacol Ther 1987;41:639-644.
8. Essig J, Belz GG, Wellstein A: The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. Br J Clin Pharmacol 1989;27(suppl):S217-S223.
9. Sedman AJ, Posvar E: Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1988;40:360-369.
10. Witte PU, Irmisch R, Hajdu P: Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor in healthy subjects. Eur J Clin Pharmacol 1984;27: 557-581.
11. Michniewicz BM, Hodges JC, England BG, Chang T, Blankly CJ, Nordblom GD: A radioimmunoassay for the diacid metabolite of CI-906, a potent angiotensin-I converting enzyme inhibitor. J Clin Immunoassay 1987;10:111-115.
12. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, et al: Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981;29:665-670.